Clinical Trial Update: A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab with pemetrexed and carboplatin in EGFR-mutant, T790M-negative NSCLC after progression on EGFR-TKI therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: NSCLC | Phase 2 | Status: COMPLETED